AIDOT, a medical AI specialist, announced on the 21st that it has succeeded in greatly reducing the size of its cervical cancer screening AI solution, “Cerviray AI.” With this optimization, Cerviray AI is now one-third the size of the previous AI model, achieving significant miniaturization. The inference speed is also more than three times faster, allowing results to be produced in under five seconds using only a CPU—no GPU required. Notably, this lightweight upgrade enables the AI to be fully on-device, providing rapid, accurate cancer screening services in underdeveloped or rural areas without the need for server equipment or network infrastructure. This is expected to greatly improve healthcare accessibility. Current cytology methods are complex, and accurate specimen collection is difficult—posing limits to effective early screening in developing countries. Failure to collect proper cell samples can lead to critical diagnostic errors, a major barrier to healthcare in vulnerable regions. By contrast, Cerviray’s AI-powered VIA (visual inspection) system enables rapid diagnosis across a wide range of environments, without relying on complex cytology specimens. Its effectiveness has already been proven through commercialization in 12 countries, including Vietnam, Indonesia, Mongolia, Bolivia, and Honduras. AIDOT CEO Jaehoon Jung stated, “Making our AI lighter and faster brings us a step closer to realizing truly inclusive healthcare services in settings with limited power, network, and infrastructure. We aim to further contribute to public health and early cancer detection in many more countries.” 

Korea Economic TV / 2025.05.21 / Senior Reporter Yang Jae-jun